Evidence map›Paper›PMID 37193190›Full record

ArticleAmerican journal of translational research2023

MiR-767-3p promotes the progression of hepatocellular carcinoma via targeting CASP-3/-9.

Maolin Wu, Jing Deng, Dejiao Yao, Shijie Li

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maolin WuDepartment of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, Sichuan, P. R. China.
Jing DengDepartment of Otolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, Sichuan, P. R. China.
Dejiao YaoDepartment of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, Sichuan, P. R. China.
Shijie LiDepartment of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, Sichuan, P. R. China.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate the relationship between miR-767-3p and hepatocellular carcinoma (HCC).

methodWe examined the expression of miR-767-3p in both HCC tissues and HCC cell lines by qRT-PCR and western blot assay. We also investigated the influence of miR-767-3p on HCC by transfecting HCC cells with either miR-767-3p mimics or inhibitors.

resultMiR-767-3p expression was increased in HCCs and cell lines. Functional analyses demonstrated that miR-767-3p increased HCC cell proliferation and prevented apoptosis both in vitro and in vivo, whereas miR-767-3p inhibition had the opposite effect. Caspase-3 and caspase-9 were found to be direct targets of miR-767-3p in HCC cell lines, and overexpression of miR-767-3p suppressed caspase-3/-9 production. Caspase-3 and caspase-9 siRNA knockdown revealed similar promoting of cell proliferation and inhibiting of cell apoptosis produced by miR-767-3p overexpression, whereas caspase-3/-9 siRNAs inhibited miR-767-3p knockdown-induced inhibition of cell proliferation and promotion of cell apoptosis.

conclusionMiR-767-3p promoted proliferation and prevented apoptosis in human hepatocellular carcinoma (HCC) through inhibiting the caspase-3/caspase-9 pathway.

Indexed as

casepasehepatocellular carcinomamiR-767-3p

Identifiers

PMID37193190
PMCPMC10182511
OpenAlexW4376871931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.